

Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2023 ASH Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following represents the mechanism of action of rufertide?
 - ACVR1/ALK2 inhibitor
 - Hepcidin memetic**
 - JAK2 inhibitor
 - XPO1 inhibitor
- Which of the following any-grade adverse events was most commonly reported in patients with JAK inhibitor-naïve myelofibrosis receiving selinexor and ruxolitinib?
 - Bruising
 - Neutropenia
 - Nausea**
 - Rash
- Which of the following JAK inhibitors has demonstrated an overall survival benefit in patients who received the full recommended dose and experienced a $\geq 10\%$ reduction in total symptom score?
 - Ruxolitinib
 - Fedratinib
 - Pacritinib**
 - Momelotinib
 - None of the above
- Which of the following JAK inhibitors is approved for patients with intermediate- or high-risk primary or secondary myelofibrosis with a platelet count below $50 \times 10^9/L$?
 - Momelotinib
 - Pacritinib**
 - Fedratinib
 - Ruxolitinib
 - All of the above
- Pelabresib targets which of the following proteins?
 - JAK1/2
 - XPO1
 - ACVR1/ALK2
 - BET**